Ropinirole HCl 91374-20-8
Product Description
.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}
Molecular Weight: 296.84 Ropinirole a selective dopamine D2 receptors agonist with Ki of 29 nM.
Ropinirole (50 mg/kg, i.p.) causes biphasic spontaneous locomotor
activity in mice. Ropinirole (0.05-1.0 mg/kg SC) dose-dependently
inhibits the dyskinesias induced by
2-di-n-propylamino-5,6-di-hydroxytetralin in mice. Ropirtirole, at doses
of 1 and 10 μg, injected unilaterally directly into the striatum of the
rat causes marked, contralateral (away from the side of injection)
asymmetry and circling in mice. Ropinirole (0.05-1.0 mg/kg SC or 0.1
mg/kg PO) reverses all motor and behavioural deficits induced by MPTP in
marmosets. Ropinirole (2 mg/kg, i.p.) for 7 days
increases GSH, catalase and SOD activities in the striatum and protected
striatal dopaminergic neurons against 6-hydroxydopamine (6-OHDA) in
mice.
Ropinirole (0.2 mg/kg, i.p.) improves the use of
previously akinetic forelimb and produced robust circling behavior in
lesioned rats with striatal over-expression of both D2R and D3R compared
to lesioned animals that received blank vector. The subtherapeutic dose
of ropinirole generates only modest motor effects in lesioned rats with
sole over-expression of D2R or D3R. Ropinirole (1-8 mg
t.i.d.) is rapidly and completely absorbed with oral bioavailability of
55%, clearance of 780 mL/min, elimination half-life of 6 hours in
healthy volunteer.
Since the major route of elimination for Ropinirole
is by the CYP enzyme system, mainly by CYP1A2 and also by CYP3A4,
inhibition of the former and possibly the latter may reduce the agent`s
clearance and lead to drug accumulation. Ropinirole (0.25
mg-4.0 mg per day) treatment significantly improves patients' ability
to initiate sleep, the amount of stage 2 sleep and sleep adequacy
compared with placebo. Periodic limb movements with arousal per hour
decreases from 7.0 to 2.5 with ropinirole but increases from 4.2 to 6.0
with placebo. Periodic limb movements while awake per hour decreases
from 56.5 to 23.6 with ropinirole but increases from 46.6 to 56.1 with
placebo.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Chemical Information
Contact us if you need more details on 91374-20-8. We are ready to answer your questions on packaging, logistics, certification or any other aspects about 91374-20-8 Ropinirole HCl、Ropinirole HCl 91374-20-8. If these products fail to match your need, please contact us and we would like to provide relevant information.
Molecular Weight: 296.84 Ropinirole a selective dopamine D2 receptors agonist with Ki of 29 nM.
Ropinirole (50 mg/kg, i.p.) causes biphasic spontaneous locomotor
activity in mice. Ropinirole (0.05-1.0 mg/kg SC) dose-dependently
inhibits the dyskinesias induced by
2-di-n-propylamino-5,6-di-hydroxytetralin in mice. Ropirtirole, at doses
of 1 and 10 μg, injected unilaterally directly into the striatum of the
rat causes marked, contralateral (away from the side of injection)
asymmetry and circling in mice. Ropinirole (0.05-1.0 mg/kg SC or 0.1
mg/kg PO) reverses all motor and behavioural deficits induced by MPTP in
marmosets. Ropinirole (2 mg/kg, i.p.) for 7 days
increases GSH, catalase and SOD activities in the striatum and protected
striatal dopaminergic neurons against 6-hydroxydopamine (6-OHDA) in
mice.
Ropinirole (0.2 mg/kg, i.p.) improves the use of
previously akinetic forelimb and produced robust circling behavior in
lesioned rats with striatal over-expression of both D2R and D3R compared
to lesioned animals that received blank vector. The subtherapeutic dose
of ropinirole generates only modest motor effects in lesioned rats with
sole over-expression of D2R or D3R. Ropinirole (1-8 mg
t.i.d.) is rapidly and completely absorbed with oral bioavailability of
55%, clearance of 780 mL/min, elimination half-life of 6 hours in
healthy volunteer.
Since the major route of elimination for Ropinirole
is by the CYP enzyme system, mainly by CYP1A2 and also by CYP3A4,
inhibition of the former and possibly the latter may reduce the agent`s
clearance and lead to drug accumulation. Ropinirole (0.25
mg-4.0 mg per day) treatment significantly improves patients' ability
to initiate sleep, the amount of stage 2 sleep and sleep adequacy
compared with placebo. Periodic limb movements with arousal per hour
decreases from 7.0 to 2.5 with ropinirole but increases from 4.2 to 6.0
with placebo. Periodic limb movements while awake per hour decreases
from 56.5 to 23.6 with ropinirole but increases from 46.6 to 56.1 with
placebo.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species | Baboon | Dog | Monkey | Rabbit | Guinea pig | Rat | Hamster | Mouse |
Weight (kg) | 12 | 10 | 3 | 1.8 | 0.4 | 0.15 | 0.08 | 0.02 |
Body Surface Area (m2) | 0.6 | 0.5 | 0.24 | 0.15 | 0.05 | 0.025 | 0.02 | 0.007 |
Km factor | 20 | 20 | 12 | 12 | 8 | 6 | 5 | 3 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Rat dose (mg/kg) = mouse dose (22.4 mg/kg) × | mouse Km(3) | = 11.2 mg/kg |
rat Km(6) |
Chemical Information
Molecular Weight (MW) | 296.84 |
---|---|
Formula | C16H24N2O.HCl |
CAS No. | 91374-20-8 |
Storage | 3 years -20℃Powder |
---|---|
6 months-80℃in solvent (DMSO, water, etc.) | |
Synonyms | |
Solubility (25°C) * | In vitro | DMSO | 10 mg/mL (33.68 mM) |
---|---|---|---|
Water | 60 mg/mL (202.12 mM) | ||
Ethanol | <1 mg/mL ( | ||
|
Chemical Name | 4-(2-(dipropylamino)ethyl)indolin-2-one hydrochloride |
---|
Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
---|---|---|---|---|
Mass(mg) | 0.29684 | 2.9684 | 5.9368 | 8.9052 |
Contact us if you need more details on 91374-20-8. We are ready to answer your questions on packaging, logistics, certification or any other aspects about 91374-20-8 Ropinirole HCl、Ropinirole HCl 91374-20-8. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : Neuronal Signaling > Dopamine Receptor Inhibitor
Other Products
Hot Products
Astragaloside AChlortetracycline HCl 64-72-2Paclitaxel 33069-62-4Dexamethasone Acetate 1177-87-3Dinaciclib (SCH727965) 779353-01-4CHIR-124 405168-58-3Ro3280 1062243-51-9TAME 901-47-3CCG-1423 285986-88-110058-F4 403811-55-2Dabigatran (BIBR 953) 211914-51-1H 89 2HCl 130964-39-5T0901317 293754-55-9Aprepitant 170729-80-3Turofexorate Isopropyl (XL335) 629664-81-9BMS-378806 357263-13-9